George Clinical is proud to have been involved in developing the recently announced recommendations by the Clinical Trial Transformation Initiative (CTTI): The Recommendations for Engaging Patients and Sites in Mobile Clinical Trials. The recommendations, to which George Clinical contributed as a member on the expert committee, aim to help research organizations, sponsors, and other stakeholders […]
Read More9 AUGUST, 2018 – (BEIJING) In another positive development in China’s rapidly evolving regulatory environment The China National Drug Administration (CNDA) has introduced a 60-day window for clinical trial approvals, mirroring US FDA protocols. The rules have taken immediate effect. “This new ruling has major implications for sponsors wishing to conduct China-only or multi-centre studies […]
Read More
Taiwan sits, along with its smaller counterparts, Singapore and Hong Kong, as one of the gateway countries to running a clinical trial in China. Although Hong Kong’s regulatory ties are more formalized with China, than Taiwan, Taiwan has the right environment and population to make the possibility of greater regulatory cohesion with its giant neighbour, […]
Read More
Clinical trial sponsors and CROs don’t need to imagine South Korea as a country of limitless potential, they know it is. South Korea is a clinical trial destination with world-class medical infrastructure, a highly-educated, relatively wealthy and healthy population. Their investigators are, on the whole, actively engaged in clinical trials and keen to play their […]
Read More
The face of individual health care is changing and improving, thanks to wearables. Wearable health and fitness devices are becoming more popular by the day and with our mobile devices and wearables prompting us to keep up with good health habits, overall health is improving too. As individuals are more aware of their health, more […]
Read More
Thrombolysis will continue to be the mainstay for acute stroke treatment, despite the recent revolution in neurointerventional clot retrieval. However, as there are ongoing limitations of thrombolysis of bleeding risk and reduced efficacy in large clots – what possible therapeutic advancements can complement or act as an adjuvant to thrombolysis? Neurointervention – effective, but limited […]
Read More
The World Health Organization states that cardiovascular disease (CVD) has been the number one global cause of death; with an estimation of 17.5 million people dying from CVD in 20121, representing 31% of all global deaths. CVD has been and is currently the major cause of death in Australia2 accounting for over 43,600 deaths in […]
Read More
Patient recruitment is crucial for the success of any clinical trial. The main objective of recruiting is to identify suitable patients that meet protocol requirements, allowing protocol questions to be answered. However, patient recruitment does not always go to plan. The leading cause of missed clinical trial deadlines is patient recruitment, taking up a significant […]
Read MoreIn this webinar, featured speakers, Professor Craig Anderson and Emma Field define and discuss the emergence of the Scientific Leadership Model as an innovative service addition to a clinical trials design and delivery in Asia. This presentation will also showcase the results and success of one of the largest obstructive sleep apnea medical device trials […]
Read More
Globally, there are millions of people that could benefit from an intensive lowering of blood pressure (BP). An individual with lower BP decreases their chances of suffering from any cardiovascular events such as: stroke, heart disease or heart attacks. A new study shows that lowering blood pressure to less than 140 mm Hg, the current […]
Read More
